ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "292: Vertex's polarizing data, Aduhelm's adieu, & an FDA icon"
Episode Synopsis
We explain the debate over Vertex Pharmaceuticals' novel pain drug, whose success in clinical trials comes with a sizable caveat. We also talk about the latest news in the life sciences, including an epitaph for Aduhelm and the retirement of an FDA icon.
Here's where you can subscribe to our biotech newsletter, The Readout. And here's where you can subscribe to our newsletter on the business (and secretive inner workings) of the U.S. health care industry, Health Care Inc.
Here's where you can subscribe to our biotech newsletter, The Readout. And here's where you can subscribe to our newsletter on the business (and secretive inner workings) of the U.S. health care industry, Health Care Inc.
More episodes of the podcast The Readout Loud
382: Biotech's year in review
18/12/2025
In God we trust